| |
Vivaldi Biosciences is a biotechnology company developing advanced vaccines for prevention of common seasonal influenza (“flu”) and emergent pandemic flu. The company is deploying world-class science leadership and patented technologies in the development and production of novel live attenuated influenza vaccines with a unique mode of action. Vivaldi’s initial focus is development of a seasonal flu vaccine that provides improved protection for adults age fifty and over. Older adults are among the most vulnerable to flu and its complications, and available vaccines generally have reduced efficacy in this age group. In preclinical studies, candidate vaccines developed using Vivaldi’s proprietary technologies induced potent and protective antibody and cellular immune responses. Animal studies also indicate the vaccines’ potential to provide long-lasting immunity and cross-protection to mismatched influenza strains with a single low-dose immunization, essential features of a long-sought “universal” flu vaccine.
|
|
|
